Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.

20-year study confirms safety of vaccines

05 Aug 2020

Vaccines have been shown to be “remarkably safe” over a 20-year period, reveals a US study.

Several safety issues have been identified via existing postmarketing surveillance programmes and are of limited clinical significance, according to the authors.

Initial and subsequent labels of all vaccines approved by the Food and Drug Administration (FDA) between 1 January 1996 and 31 December 2015 were included in this retrospective cohort study. The authors performed a descriptive analysis of the prevalence and characteristics of postapproval, safety-related label changes, and described the distribution of data sources triggering these modifications.

Fifty-seven FDA-approved vaccines were analysed, of which 53 (93 percent) had initial approval supported by randomized controlled trials, with a median cohort size of 4,161 participants (interquartile range, 2,204–8,634). Fifty-eight postapproval, safety-related label modifications were associated with 25 vaccines (49 warnings and precautions, eight contraindications, and one safety-related withdrawal).

The initial approval trial characteristics were similar in vaccines with and without postmarketing, safety-related label modifications. Expansion of populations restrictions (n=21, 36 percent) was the most common safety issue prompting label modifications, followed by allergies (n=13, 22 percent). Moreover, postmarketing surveillance (n=28 of 58, 48 percent) was the most common source of safety data.

“These findings confirm the robustness of the vaccine approval system and postmarketing surveillance,” the authors said.

With regard to the limitations of this study, all safety data received and processed by the FDA were not necessarily represented by the data sources of the initial signal triggering safety-related label changes, according to the authors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.